References
- Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers? Pharmacoeconomics 2007;25:467-79
- Keehan SP, Stone DA, Poisal JA, et al. National health expenditure projections, 2016–25: price increases, aging push sector to 20 percent of economy. Health Aff (Millwood) 2017;36:553-63
- Peking University, Fudan University, China Pharmaceutical University, et al. China guidelines for pharmacoeconomic evaluations; 2011. Available at: https://www.ispor.org/PEguidelines/source/China-Guidelines-for-Pharmacoeconomic-Evaluations_2011_Chinese.pdf
- Zafari Z, Bryan S, Sin DD, et al. A systematic review of health economics simulation models of chronic obstructive pulmonary disease. Value Health 2017;20:152-62
- Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol 1997;43:343-8
- Ho MY, Chan KK, Peacock S, et al. Improving the quality of abstract reporting for economic analyses in oncology. Curr Oncol 2012;19:e428-35
- Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83
- Haddad FS, McLawhorn AS. Guidelines for reporting health economic research. Bone Joint J 2016;98-B:147-51
- Hjelmgren J, Berggren F, Andersson F. Health economic guidelines—similarities, differences and some implications. Value Health 2001;4:225-50
- Jacobs P, Ohinmaa A, Brady B. Providing systematic guidance in pharmacoeconomic guidelines for analysing costs. Pharmacoeconomics 2005;23:143-53
- Knies S, Severens JL, Ament AJ, et al. The transferability of valuing lost productivity across jurisdictions. Differences between national pharmacoeconomic guidelines. Value Health 2010;13:519-27
- EUnetHTA Joint Action, Work Package, Subgroup, Heintz E, et al. Is there a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries. Pharmacoeconomics 2016;34:59-76
- Bracco A, Krol M. Economic evaluations in European reimbursement submission guidelines: current status and comparisons. Expert Rev Pharmacoecon Outcomes Res 2013;13:579-95
- Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 5.0). Australian Government - Department of Health; 2016
- Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa, Canada: CADTH; 2006. Available at: https://www.ispor.org/PEguidelines/source/HTAGuidelinesfortheEconomicEvaluationofHealthTechnologies-Canada.pdf
- Drummond MF. Guidelines for pharmacoeconomic studies. The ways forward. Pharmacoeconomics 1994;6:493-7
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535
- Clemens K, Townsend R, Luscombe F, et al. Methodological and conduct principles for pharmacoeconomic research. Pharmacoeconomics 1995;8:169-74
- Detsky AS. Guidelines for economic analysis of pharmaceutical products a draft document for ontario and Canada. Pharmacoeconomics 1993;3:354-61
- Graf von der Schulenburg JM, Hoffmann C. Review of European guidelines for economic evaluation of medical technologies and pharmaceuticals. Eur J Heath Econ (HEPAC) 2000;1:2-8
- Graf von der Schulenberg JM, Greiner W, Jost F, et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 2008;11:539-44
- Guyatt G, Drummond M, Feeny D, et al. Guidelines for the clinical and economic evaluation of health care technologies. Soc Sci Med 1986;22:393-408
- Langley PC. Formulary submission guidelines for Blue Cross and Blue Shield of Colorado and Nevada. Structure, application and manufacturer responsibilities. Pharmacoeconomics 1999;16:211-24
- Task Force on Principles for Economic Analysis of Healthcare Technology. Economic analysis of health care technology—a report on principles. Ann Int Med 1995;122:61-70
- Walter E, Zehetmayr S. Guidelines on health economic evaluation, consensus paper. Vienna: Institute for Pharmaeconomic Research [IPF]; 2006
- Behmane D, Lambot K, Irs A, et al. N. Baltic guideline for economic evaluation of pharmaceuticals (pharmacoeconomic analysis). Eesti Haigekassa [Estonian Health Insurance Fund]; 2002. Available at: https://www.ispor.org/PEguidelines/source/Baltic-PE-guideline.pdf
- Belgian Heath Care Knowledge Centre [KCE]. Belgian guidelines for economic evaluations and budget impact analyses: second edition. KCE Report 183C. Brussels: KCE; 2012
- Agency for Quality and Accreditation in Health Care, Department for Development, Research and Health Technology Assessment. The Croatian Guideline for Health Technology Assessment Process and Reporting, 1st ed Zagreb, February 2011. http://aaz.hr/sites/default/files/hrvatske_smjernice_za_procjenu_zdravstvenih_tehnologija.pdf.
- Alban A, Gyldmark M, Pedersen AV, et al. The Danish approach to standards for economic evaluation methodologies. Pharmacoeconomics 1997;12:627-36
- Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs. Guidelines for reporting pharmacoeconomic evaluations in Egypt; 2013. Available at: http://www.eda.mohp.gov.eg/Files/402_Egyptian_Pharmacoeconomic_guidelines.pdf
- National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2013. Available at: https://www.nice.org.uk/guidance/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
- Pharmaceuticals Pricing Board. Preparing a health economic evaluation to be attached to the application for reimbursement status and wholesale price for a medicinal product. Pharmaceuticals Pricing Board; 2015. Available at: http://www.hila.fi/c/document_library/get_file?folderId = 793451&name=DLFE-9132.pdf
- The members of the Collège des Économistes de la Santé (the French Health Economists Association). French guidelines for the economic evaluation of health care technologies; September 2004. Available at: https://www.ispor.org/PEguidelines/source/France_Guidelines_HE_Evaluation.pdf
- Institute for Quality and Efficiency in Health Care (IQWiG). General methods for the assessment of the relation of benefits to costs. Version 1.0. Available at: https://www.ispor.org/PEguidelines/source/Germany_AssessmentoftheRelationofBenefitstoCosts_En.pdf
- Szende A, Mogyorosy Z, Muszbek N, et al. Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards. Eur J Health Econ 2002;3:196-206
- Health Information and Quality Authority [HIQA]. Guidelines for the economic evaluation of health technologies in Ireland. Cork: HIQA; 2010. Available at: https://www.ispor.org/PEguidelines/source/Ireland_Economic_Guidelines_2010.pdf
- Pharmacoepidemiology and Pharmacoeconomics Department, Pharmaceutical Administration of the Ministry of Health. Guidelines for the submission of a request to include a pharmaceutical product in the national list of health services. Available at: https://www.ispor.org/PEguidelines/source/Israel-Guidelines-for-submission_2010.pdf
- Capri S, Ceci A, Terranova L, et al. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Info J 2001;35:189-201
- Pharmaceutical Services Division, Ministry of Health Malaysia. Pharmacoeconomic guideline for Malaysia; 2012. Available at: https://www.ispor.org/PEguidelines/source/PEguidelines-Malaysia.pdf
- The Pharmaceutical Management Agency (PHARMACA). Prescription for pharmacoeconomic analysis: methods for cost-utility analysis, Version 2.2; August 2015. Available at: https://www.pharmac.govt.nz/assets/pfpa-2-2.pdf
- Norwegian Medicines Agency [NOMA]. Guidelines on how to conduct pharmacoeconomic analyses. Oslo: NOMA; 2012. Available at: https://www.ispor.org/PEguidelines/source/Norwegian_guidelines2012.pdf
- Agency for Health Technology Assessment. Guidelines for conducting health technology assessment (HTA). Version 2.1 (Part 4 & 5). Warsaw, Poland: Agency for Health Technology Assessment; April 2009. Available at: https://www.ispor.org/PEguidelines/source/Poland_Guidelines-for-Conducting-HTA_English-Version.pdf
- Alves da Silva E, Gouveia Pinto C, Sampaio C, et al. Guidelines for economic drug evaluation studies. Lisbon: National Authority of Medicines and Health Products [INFARMED]; 1998. Available at: https://www.ispor.org/PEguidelines/source/PE%20guidelines%20in%20English_Portugal.pdf
- ISPOR, Russian State Medical University. Protocol on the procedure for clinical and economic evaluation of drugs which are submitted for inclusion into reimbursed drug lists, Moscow: ISPOR; 2010. Available at: https://www.ispor.org/PEguidelines/source/Russia_PE_Recommendations_english_fnal_13_03.pdf
- Scottish Medicines Consortium [SMC]. Guidance to manufacturers for completion of new product assessment form (NPAF); Revised June 2007. Available at: https://www.ispor.org/PEguidelines/source/GuidanceinScotland-June2007.pdf
- National Department of Health. Guidelines for pharmacoeconomic submissions; December 2012. Available at: https://www.ispor.org/PEguidelines/source/PEGazette_February2013_SouthAfrica.pdf
- López-Bastida J, Oliva J, Antonãnzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010;11:513-20
- Dental and Pharmaceutical Benefits Agency [TLV]. General guidelines for economic evaluations from the Pharmaceutical Benefits Board. Stockholm, Sweden: TLV; 2003. Available at: https://www.ispor.org/PEguidelines/source/Guidelines_in_Sweden.pdf
- Taiwan Society for Pharmacoeconomic and Outcomes Research (TaSPOR). Guidelines of methodological standards for pharmacoeconomic evaluations in Taiwan (Version 1.0); 2006. Available at: https://www.ispor.org/PEguidelines/source/2006_PEG_EN_2009.pdf
- Universities, ISPOR, and HITAP (Health Intervention and Technology Assessment Program), Ministry of Public Health. Health technology assessment guideline; 2008. Available at: https://www.ispor.org/PEguidelines/source/Thailand-Health-Technology-Assessment-Guidelines.pdf
- National Health Care Institute. Guideline for the conduct of economic evaluations in health care (Dutch version); February 2016. Available at: https://www.ispor.org/PEguidelines/countrydet.asp?c=22&t=1
- AMCP Format Executive Committee members. The AMCP format for formulary submissions (Version 4.0); April 2016. Available at: http://www.amcp.org/FormatV4/
- Mathes T, Jacobs E, Morfeld JC, et al. Methods of international health technology assessment agencies for economic evaluations–a comparative analysis. BMC Health Serv Res 2013;13:371
- Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008;24:244-58
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093-103
- Sculpher MJ, Drummond MF. Analysis sans frontieres: can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics 2006;24;1087-99